STAAR Surgical (STAA) Projected to Announce Earnings on Wednesday

STAAR Surgical (NASDAQ:STAA) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect STAAR Surgical to post earnings of $0.21 per share and revenue of $90.5890 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:30 PM ET.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The company had revenue of $93.52 million for the quarter, compared to the consensus estimate of $78.72 million. During the same quarter last year, the company earned ($1.10) earnings per share. The firm’s revenue for the quarter was up 119.6% compared to the same quarter last year. On average, analysts expect STAAR Surgical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

STAAR Surgical Price Performance

STAA opened at $24.12 on Wednesday. The business’s 50-day moving average is $27.60 and its two-hundred day moving average is $23.93. STAAR Surgical has a 1 year low of $15.59 and a 1 year high of $35.87. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.12 and a quick ratio of 4.31. The firm has a market capitalization of $1.20 billion, a PE ratio of -56.09 and a beta of 1.26.

Institutional Investors Weigh In On STAAR Surgical

Several institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its stake in shares of STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 1,016 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of STAAR Surgical by 375.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 4,673 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in STAAR Surgical by 9,928.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock worth $121,000 after purchasing an additional 4,468 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in STAAR Surgical in the 3rd quarter worth approximately $208,000. Finally, Amundi purchased a new stake in STAAR Surgical during the 3rd quarter worth approximately $251,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a research report on Thursday, May 14th. Wells Fargo & Company increased their target price on shares of STAAR Surgical from $16.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday, May 15th. Canaccord Genuity Group increased their target price on shares of STAAR Surgical from $27.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Weiss Ratings upgraded shares of STAAR Surgical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 25th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of STAAR Surgical in a report on Tuesday. Three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $26.94.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.